Oroxine | US Patents | Expiry | Expiration | Dates | PharmaCompass.com

Please Wait

Applying Filters...

Grow Your Pharma Business Digitally

Find Suppliers : API/FDF
- Search Our Integrated Database
Services
Excipients
Drugs in Dev.
News
Blog
Market Place
Login

Oroxine
US Patents

Zach System is committed to providing Highly Customized Solutions for all your Development Programs.

Contact Supplier

Mission CDMO team brings reliability, resourcefulness, & responsiveness in executing your development project.

Contact Supplier

Arlanda is your partner for the Brazil market.

Contact Supplier

SPI Pharma has been solving formulation challenges using superior functional materials.

Contact Supplier

AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

Contact Supplier

xyz-pharma-m-2025-03-17

Contact Supplier

Oroxine

ACCESS ALL DATA, CHEMISTRY

ACCESS ALL DATA
Browse all information
CHEMISTRY
Discover Molecule Insights

ACTIVE PHARMA INGREDIENTS

28 API Suppliers, 15 USDMF, 10 CEP/COS, 2 JDMF, 5 EU WC, 5 KDMF, 20 NDC API, 14 Listed Suppliers, $ API Reference Price

28 API Suppliers
15 USDMF
10 CEP/COS
2 JDMF
5 EU WC
5 KDMF
20 NDC API
14 Listed Suppliers
$ API Reference Price

DEVELOPMENTS

9 Drugs in Development

9 Drugs in Development

INTERMEDIATES

5 Intermediate Suppliers

5 Intermediate Suppliers

FINISHED DOSAGE FORMULATIONS

591 FDF Dossiers, 264 FDA Orange Book, 187 Europe, 29 Canada, 37 Australia, 19 South Africa, 55 Listed Dossiers

591 FDF Dossiers
264 FDA Orange Book
187 Europe
29 Canada
37 Australia
19 South Africa
55 Listed Dossiers

DRUG PRODUCT COMPOSITIONS

TABLET;ORAL - 0.0125MG;0.0031MG, TABLET;ORAL - 0.025MG;0.0063MG, TABLET;ORAL - 0.05MG;0.0125MG, TABLET;ORAL - 0.15MG;0.0375MG, TABLET;ORAL - 0.1MG;0.025MG, POWDER;INTRAVENOUS - 100MCG/VIAL, POWDER;INTRAVENOUS - 200MCG/VIAL, POWDER;INTRAVENOUS - 500MCG/VIAL, TABLET;ORAL - 0.025MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium, TABLET;ORAL - 0.05MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium, TABLET;ORAL - 0.075MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium, TABLET;ORAL - 0.088MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium, TABLET;ORAL - 0.112MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium, TABLET;ORAL - 0.125MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium, TABLET;ORAL - 0.137MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium, TABLET;ORAL - 0.15MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium, TABLET;ORAL - 0.175MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium, TABLET;ORAL - 0.1MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium, TABLET;ORAL - 0.2MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium, TABLET;ORAL - 0.3MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium, TABLET;ORAL - 0.025MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium, TABLET;ORAL - 0.05MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium, TABLET;ORAL - 0.075MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium, TABLET;ORAL - 0.088MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium, TABLET;ORAL - 0.112MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium, TABLET;ORAL - 0.125MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium, TABLET;ORAL - 0.137MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium, TABLET;ORAL - 0.15MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium, TABLET;ORAL - 0.175MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium, TABLET;ORAL - 0.1MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium, TABLET;ORAL - 0.2MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium, TABLET;ORAL - 0.3MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium, TABLET;ORAL - 0.025MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium, TABLET;ORAL - 0.05MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium, TABLET;ORAL - 0.075MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium, TABLET;ORAL - 0.088MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium, TABLET;ORAL - 0.112MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium, TABLET;ORAL - 0.125MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium, TABLET;ORAL - 0.137MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium, TABLET;ORAL - 0.15MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium, TABLET;ORAL - 0.175MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium, TABLET;ORAL - 0.1MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium, TABLET;ORAL - 0.2MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium, TABLET;ORAL - 0.3MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium, CAPSULE;ORAL - 0.013MG, CAPSULE;ORAL - 0.025MG, CAPSULE;ORAL - 0.0375MG, CAPSULE;ORAL - 0.044MG, CAPSULE;ORAL - 0.05MG, CAPSULE;ORAL - 0.0625MG, CAPSULE;ORAL - 0.075MG, CAPSULE;ORAL - 0.088MG, CAPSULE;ORAL - 0.112MG, CAPSULE;ORAL - 0.125MG, CAPSULE;ORAL - 0.137MG, CAPSULE;ORAL - 0.15MG, CAPSULE;ORAL - 0.175MG, CAPSULE;ORAL - 0.1MG, CAPSULE;ORAL - 0.2MG

TABLET;ORAL - 0.0125MG;0.0031MG
TABLET;ORAL - 0.025MG;0.0063MG
TABLET;ORAL - 0.05MG;0.0125MG
TABLET;ORAL - 0.15MG;0.0375MG
TABLET;ORAL - 0.1MG;0.025MG
POWDER;INTRAVENOUS - 100MCG/VIAL
POWDER;INTRAVENOUS - 200MCG/VIAL
POWDER;INTRAVENOUS - 500MCG/VIAL
TABLET;ORAL - 0.025MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium
TABLET;ORAL - 0.05MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium
TABLET;ORAL - 0.075MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium
TABLET;ORAL - 0.088MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium
TABLET;ORAL - 0.112MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium
TABLET;ORAL - 0.125MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium
TABLET;ORAL - 0.137MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium
TABLET;ORAL - 0.15MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium
TABLET;ORAL - 0.175MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium
TABLET;ORAL - 0.1MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium
TABLET;ORAL - 0.2MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium
TABLET;ORAL - 0.3MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium
TABLET;ORAL - 0.025MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium
TABLET;ORAL - 0.05MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium
TABLET;ORAL - 0.075MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium
TABLET;ORAL - 0.088MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium
TABLET;ORAL - 0.112MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium
TABLET;ORAL - 0.125MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium
TABLET;ORAL - 0.137MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium
TABLET;ORAL - 0.15MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium
TABLET;ORAL - 0.175MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium
TABLET;ORAL - 0.1MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium
TABLET;ORAL - 0.2MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium
TABLET;ORAL - 0.3MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium
TABLET;ORAL - 0.025MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium
TABLET;ORAL - 0.05MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium
TABLET;ORAL - 0.075MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium
TABLET;ORAL - 0.088MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium
TABLET;ORAL - 0.112MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium
TABLET;ORAL - 0.125MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium
TABLET;ORAL - 0.137MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium
TABLET;ORAL - 0.15MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium
TABLET;ORAL - 0.175MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium
TABLET;ORAL - 0.1MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium
TABLET;ORAL - 0.2MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium
TABLET;ORAL - 0.3MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium
CAPSULE;ORAL - 0.013MG
CAPSULE;ORAL - 0.025MG
CAPSULE;ORAL - 0.0375MG
CAPSULE;ORAL - 0.044MG
CAPSULE;ORAL - 0.05MG
CAPSULE;ORAL - 0.0625MG
CAPSULE;ORAL - 0.075MG
CAPSULE;ORAL - 0.088MG
CAPSULE;ORAL - 0.112MG
CAPSULE;ORAL - 0.125MG
CAPSULE;ORAL - 0.137MG
CAPSULE;ORAL - 0.15MG
CAPSULE;ORAL - 0.175MG
CAPSULE;ORAL - 0.1MG
CAPSULE;ORAL - 0.2MG

RELATED EXCIPIENT COMPANIES

2 EUROAPI, 3 Rochem International Inc, 21 SPI Pharma, 9 DKSH, 9 Faran Shimi Pharmaceutical, 1 Boai NKY Pharmaceuticals Ltd, 7 Gangwal Healthcare, 2 Nanjing Well Pharmaceutical, 2 Pfanstiehl, 4 ACG Worldwide, 6 Actylis, 2 Aeon Procare, 8 Anhui Sunhere Pharmaceutical Excipients Co.,Ltd, 16 BASF, 10 Corel Pharma Chem, 6 DFE Pharma, 1 Finar, 7 Gangwal Chemicals, 5 Ideal Cures Pvt Ltd, 5 Ingredion Pharma Solutions, 31 Kerry, 3 Kima Chemical, 6 Lonza Capsugel, 15 Microlex e.U, 2 Novo Excipients, 3 Pharmatrans-Sanaq, 10 Pluviaendo, 4 Prachin Chemical, 1 Qianhao Chemical (Hebei) Co., Ltd, 2 Qualicaps, 31 Roquette, 7 Seppic, 7 Shanghai Shenmei Pharmaceutical Technology Co., Ltd, 1 Shijiazhuang Huaxu Pharmaceutical, 12 Sigachi Industries, 2 The Dow Chemical Company, 1 Valens Pharmachem, 5 Vasa Pharmachem

EXCIPIENTS BY APPLICATIONS

88 Fillers, Diluents & Binders, 43 Coating Systems & Additives, 33 Direct Compression, 31 Disintegrants & Superdisintegrants, 28 Thickeners and Stabilizers, 26 Granulation, 24 Controlled & Modified Release, 24 Taste Masking, 20 Parenteral, 19 Chewable & Orodispersible Aids, 19 Lubricants & Glidants, 15 Solubilizers, 14 Co-Processed Excipients, 9 Film Formers & Plasticizers, 9 Empty Capsules, 7 API Stability Enhancers, 7 Topical, 6 Emulsifying Agents, 5 Rheology Modifiers, 4 Vegetarian Capsules, 2 Coloring Agents, 1 Surfactant & Foaming Agents

88 Fillers, Diluents & Binders
43 Coating Systems & Additives
33 Direct Compression
31 Disintegrants & Superdisintegrants
28 Thickeners and Stabilizers
26 Granulation
24 Controlled & Modified Release
24 Taste Masking
20 Parenteral
19 Chewable & Orodispersible Aids
19 Lubricants & Glidants
15 Solubilizers
14 Co-Processed Excipients
9 Film Formers & Plasticizers
9 Empty Capsules
7 API Stability Enhancers
7 Topical
6 Emulsifying Agents
5 Rheology Modifiers
4 Vegetarian Capsules
2 Coloring Agents
1 Surfactant & Foaming Agents

DIGITAL CONTENT

1 Data Compilation #PharmaFlow, 89 News #PharmaBuzz

1 Data Compilation #PharmaFlow
89 News #PharmaBuzz

GLOBAL SALES INFORMATION

8 US Medicaid Prescriptions, 177 Regulatory FDF Prices, 8 Annual Reports

8 US Medicaid Prescriptions
177 Regulatory FDF Prices
8 Annual Reports

MARKET PLACE

30 APIs, 14 FDF Dossiers

30 APIs
14 FDF Dossiers

PATENTS & EXCLUSIVITIES

101 US Patents

101 US Patents

REF. STANDARDS & IMPURITIES

3 EDQM, 3 USP, 3 Others

3 EDQM
3 USP
3 Others

ANALYTICAL

1 BioAnalytical Methods

1 BioAnalytical Methods

$ API Ref.Price (USD/KG) : 6,663 Xls

Filters

Reset all filters

Filters

FILTER :

filter Applicant Reset all filters

101 All

01 1AZURITY

02 18FRESENIUS KABI USA

03 20GENUS LIFESCIENCES

04 1HIKMA

05 60IBSA

06 1MYLAN

filter Patent Number Reset all filters

101 All

01 39006289

02 19050307

03 39168238

04 39168239

05 19345772

06 39782376

07 1010231931

08 310398669

09 1010406108

10 1510537538

11 1511096913

12 311135190

13 111154498

14 3011241382

filter API Patent Reset all filters

101 All

01 101Blank

filter FDF Patent Reset all filters

101 All

01 71Y

02 30Blank

filter Expiration Date Reset all filters

101 All

01 12031-08-06

02 62032-08-29

03 32032-10-03

04 12035-02-27

05 12036-07-20

06 92036-12-01

07 302037-02-28

08 202038-03-23

09 302039-09-17

Product Main Page

01

AZURITY

LEVOTHYROXINE SODIUM

ATTD

Not Confirmed

AZURITY

ATTD

Not Confirmed

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

Patent Expiration Date : 2031-08-06

LEVOTHYROXINE SODIUM

US Patent Number : 9050307

Drug Substance Claim :

Drug Product Claim : Y

Application Number : 214047

Patent Use Code :

Delist Requested :

Patent Use Description :

Patent Expiration Date : 2031-08-06

Portfolio PDF

Product Web Link

Digital Content

Corporate PDF

02

FRESENIUS KABI USA

LEVOTHYROXINE SODIUM

ATTD

Not Confirmed

FRESENIUS KABI USA

ATTD

Not Confirmed

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

Patent Expiration Date : 2036-12-01

LEVOTHYROXINE SODIUM

US Patent Number : 9782376

Drug Substance Claim :

Drug Product Claim : Y

Application Number : 210632

Patent Use Code :

Delist Requested :

Patent Use Description :

Patent Expiration Date : 2036-12-01

Portfolio PDF

Product Web Link

Digital Content

Corporate PDF

03

FRESENIUS KABI USA

LEVOTHYROXINE SODIUM

ATTD

Not Confirmed

FRESENIUS KABI USA

ATTD

Not Confirmed

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

Patent Expiration Date : 2032-08-29

LEVOTHYROXINE SODIUM

US Patent Number : 9168238

Drug Substance Claim :

Drug Product Claim : Y

Application Number : 202231

Patent Use Code :

Delist Requested :

Patent Use Description :

Patent Expiration Date : 2032-08-29

Portfolio PDF

Product Web Link

Digital Content

Corporate PDF

04

FRESENIUS KABI USA

LEVOTHYROXINE SODIUM

ATTD

Not Confirmed

FRESENIUS KABI USA

ATTD

Not Confirmed

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

Patent Expiration Date : 2036-12-01

LEVOTHYROXINE SODIUM

US Patent Number : 9782376

Drug Substance Claim :

Drug Product Claim : Y

Application Number : 210632

Patent Use Code :

Delist Requested :

Patent Use Description :

Patent Expiration Date : 2036-12-01

Portfolio PDF

Product Web Link

Digital Content

Corporate PDF

05

FRESENIUS KABI USA

LEVOTHYROXINE SODIUM

ATTD

Not Confirmed

FRESENIUS KABI USA

ATTD

Not Confirmed

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

Patent Expiration Date : 2032-08-29

LEVOTHYROXINE SODIUM

US Patent Number : 9168239

Drug Substance Claim :

Drug Product Claim : Y

Application Number : 202231

Patent Use Code :

Delist Requested :

Patent Use Description :

Patent Expiration Date : 2032-08-29

Portfolio PDF

Product Web Link

Digital Content

Corporate PDF

06

FRESENIUS KABI USA

LEVOTHYROXINE SODIUM

ATTD

Not Confirmed

FRESENIUS KABI USA

ATTD

Not Confirmed

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

Patent Expiration Date : 2036-12-01

LEVOTHYROXINE SODIUM

US Patent Number : 11135190

Drug Substance Claim :

Drug Product Claim : Y

Application Number : 210632

Patent Use Code :

Delist Requested :

Patent Use Description :

Patent Expiration Date : 2036-12-01

Portfolio PDF

Product Web Link

Digital Content

Corporate PDF

07

FRESENIUS KABI USA

LEVOTHYROXINE SODIUM

ATTD

Not Confirmed

FRESENIUS KABI USA

ATTD

Not Confirmed

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

Patent Expiration Date : 2032-08-29

LEVOTHYROXINE SODIUM

US Patent Number : 9168238

Drug Substance Claim :

Drug Product Claim : Y

Application Number : 202231

Patent Use Code :

Delist Requested :

Patent Use Description :

Patent Expiration Date : 2032-08-29

Portfolio PDF

Product Web Link

Digital Content

Corporate PDF

08

FRESENIUS KABI USA

LEVOTHYROXINE SODIUM

ATTD

Not Confirmed

FRESENIUS KABI USA

ATTD

Not Confirmed

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

Patent Expiration Date : 2032-08-29

LEVOTHYROXINE SODIUM

US Patent Number : 9168239

Drug Substance Claim :

Drug Product Claim : Y

Application Number : 202231

Patent Use Code :

Delist Requested :

Patent Use Description :

Patent Expiration Date : 2032-08-29

Portfolio PDF

Product Web Link

Digital Content

Corporate PDF

09

FRESENIUS KABI USA

LEVOTHYROXINE SODIUM

ATTD

Not Confirmed

FRESENIUS KABI USA

ATTD

Not Confirmed

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

Patent Expiration Date : 2036-12-01

LEVOTHYROXINE SODIUM

US Patent Number : 10398669

Drug Substance Claim :

Drug Product Claim : Y

Application Number : 210632

Patent Use Code :

Delist Requested :

Patent Use Description :

Patent Expiration Date : 2036-12-01

Portfolio PDF

Product Web Link

Digital Content

Corporate PDF

10

FRESENIUS KABI USA

LEVOTHYROXINE SODIUM

ATTD

Not Confirmed

FRESENIUS KABI USA

ATTD

Not Confirmed

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

Patent Expiration Date : 2036-12-01

LEVOTHYROXINE SODIUM

US Patent Number : 11135190

Drug Substance Claim :

Drug Product Claim : Y

Application Number : 210632

Patent Use Code :

Delist Requested :

Patent Use Description :

Patent Expiration Date : 2036-12-01

Portfolio PDF

Product Web Link

Digital Content

Corporate PDF

1
2
3
Last

Contact us
to update this info

Privacy policy
Terms and conditions
Disclaimers
Ask Us!